Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperemmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients

Annals of Pharmacotherapy

Volumn 30, Issue 12, 1996, Pages 1452-1464

  Dickinson, Benjamin I ^a,b,g   Gora Harper, Mary Lea ^c   McCraney, Scott A ^d,e   Gosland, Michael ^f  

^a UNIVERSITY OF KENTUCKY   (United States)

^b AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d WellStar Kennestone Hospital   (United States)

^e Pharmasource Healthcare Inc   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

BACKACHE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MUSCLE CRAMP; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; REVIEW;

ACYCLOVIR; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION;

EID: 0030472619     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001215     Document Type: Article

References (35)

1. According to facsimile from United Network for Organ Sharing. UNOSOPTN and Scientific Registry Data. Richmond, VA: April 1996.
2. Griffith PD. Cytomegalovirus. In: Zucherman AJ, Banatvala JE, Pattison JR, eds. Principles and practice of clinical virology. 2nd ed. Chichester, England: John Wiley and Sons, 1990:69-102.
3. Glenn J. Cytomegalovirus infections following renal transplantation. Rev Infect Dis 1981;3:1151-78.
4. McCarthy M, Karim M, Krueger H, Keown P. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993;555:1277-82.
5. Tsevat J, Snydman DR, Pauker SG, Durand-Zaleski I, Werner BG, Levey AS. Which renal transplant patients should receive cytomegalovirus immune globulin? Transplantation 1991:52;259-65.
6. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990;12(suppl):S701-10.
7. Snydman DR, Rubin RH, Werner BG. New developments in cytomegalovirus prevention and management. Am J Kidney Dis 1993;21:217-28.
8. Fassbinder W, Bechstein PB, Scheuermann EH, Schoeppe W. Incidence of cytomegalovirus-infection after renal transplantation and first experiences with prophylactic hyperimmunoglobulin. Scan J Urol Nephrol 1985;92(suppl):23-8.
9. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7.
10. Fletcher CV, Chinnock BJ, Chase B. Pharmacokinetics and safety of high-dose oral acyclovir for suppression of CMV disease after renal transplantation. Clin Pharmacol Ther 1988;44:158-63.
11. Vasquez EM, Sanchez J, Pollak R, Vrahnos D, Fabrega AJ, Maddux MS. High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients. Transplantation 1992;55:448-50.
12. Conti DJ, Freed BM, Gruber SA, Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch Surg 1994;129:443-7.
13. Steinmuller DR, Novick AC, Streem SB, Graneto D, Swift C. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation 1990;49:68-70.
14. Conti DJ, Freed BM, Lempert N. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients as risk for primary cytomegalovirus disease. Transplant Proc 1993;25:1421-2.
15. Khawand N, Light JA, Brems W, Aquino A, Ali A. Does intravenous immunoglobulin prevent primary cytomegalovirus disease in kidney transplant recipients? Transplant Proc 1989;21:2072-4.
16. Steinmuller DR, Graneto D, Swift C, Novick AC, Streem SB, Cunningham RJ, et al. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation. Transplant Proc 1989;21:2069-71.
17. Kasiske BL, Heim-Duthoy KL, Tortorice KL, Ney AL, Odland MD, Rao KV. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 1989;149:2733-6.
18. Werner BG, Snydman DR, Freeman R, Rohrer R, Tilney ML, Kirkman RL, et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. Transplant Proc 1993;25:1441-3.
19. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049-54.
20. Snydman DR, Werner BG, Tilney NL, Kirkman RL, Milford EL, Cho SI, et al. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplant Proc 1991;23:1357-60.
21. Fassbinder W, Ernst W, Hanke P, Schoeppe W. Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transplant Proc 1986;18:1393-6.
22. Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 1992;67:879-90.
23. Ho M. Cytomegalovirus: biology and infection. New York: Plenum Medical Book, 1982.
24. Drug topics red book 1996. Montvale, NJ: Medical Economics Data, Inc., 1996:205,442,512.
25. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. N Engl J Med 1991;324:1005-11.
26. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 1991;114:525-31.
27. Aulilzky WE, Schulz TF, Tilg H, Niedemieser D, Larcher K, Ostberg L, et al. Human monoclonal antibodies neutralizing cytomegalovirus for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. J Infect Dis 1991;163:1344-7.
28. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, et al. Human cytomegalovirus-specific cytotoxic T cells. J Exp Med 1988;168:919-31.
29. Graham S, Green CP, Mason PD, Borsiewicz LK. Human cytotoxic T cell responses to vaccinia virus vaccination. J Gen Virol 1991;72:1183-6.
30. Klintmalm G, Lonnquist B, Oberg B, Gahrton G, Lernestedt J, Lundgren G, et al. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis 1985;17:157-63.
31. Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994;57:876-84.
32. Wagstaff AJ, Faulds D, Goa KL. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties, and therapeutic efficacy. Drugs 1994;47:150-205.
33. Smec DF. Interaction of 9-(1,3-dihydroxy-2-propoxymethyl)guanine with cytosol and mitochondrial deoxyguanosine kinases: possible role in anti-cytomegalovirus activity. Mol Cell Biochem 1985;69:75-81.
34. Gratwohl A, Doran JE, Bachmann P, Scherz R, Spath P, Baumgartner C, et al. Serum concentrations of immunoglobulins and of antibody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmune globulin. Bone Marrow Transplant 1991;8:275-82.
35. Snydman DR. Cytomegalovirus infection in solid organ transplantation: prospects for prevention. Transplant Rev 1990;4:59.